Oral tofacitinib monotherapy with fire needling induced marked regression of cutaneous Rosai-Dorfman disease lesions in a single patient.
A pill and a heated needle tamed a stubborn face disease
This case report and literature review describes a 55-year-old female with refractory cutaneous Rosai-Dorfman disease who failed prior thera…
A woman whose face was covered in stubborn red nodules finally saw improvement when doctors tried a surprising combination that crossed medi…
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
Review explores JAK inhibitor combination with PD-1 blockade for overcoming immunotherapy resistance
Review explores combining JAK inhibitors with immunotherapy for resistant cancers
A systematic review discusses the rationale for combining JAK inhibitors with PD-1 blockade immunotherapy based on emerging preclinical and …
Blocking inflammation around tumors with JAK inhibitors may help immune drugs work better for cancers that have stopped responding to standa…
Tofacitinib used in single case of steroid-refractory multi-organ immune-related adverse events
Single case shows tofacitinib may help with severe immune side effects from cancer immunotherapy
A case report describes a 75-year-old female with colon cancer who developed steroid-refractory immune checkpoint inhibitor-associated myoca…
A single case shows tofacitinib helped a cancer patient recover from severe heart inflammation that steroids could not fix, though infection…